Estimated Veterans Health Administration costs for Alzheimer's disease treatment with aducanumab
Haimovich, A. D.; Goulet, J. L.; Brandt, C. A.; Tarabar, A.; Patwa, H. S.; Hwang, U.
Show abstract
The approval of aducanumab for the treatment of Alzheimers disease has been met with significant public concern. Projections of annual cost across United States Medicare beneficiaries are in the tens of billions of dollars. Here, we performed an electronic health record review of Veterans Affairs beneficiaries, identifying 151,921 individuals (1.7%) with diagnosis codes for Alzheimers disease. We estimate that treatment for this cohort will cost in excess of $4 billion annually with further expenditures for associated screening, consultations, imaging, and therapeutic monitoring. The magnitude of projected expenditures necessitates early assessment of drug cost effectiveness.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research 93%
- Real-world datasets for the International Registry for Alzheimer’s Disease and Other Dementias (InRAD) and other registries: an international consensus 90%
- Continuous Associations Between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease 88%
Similar papers in this journal
- Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial 86%
- Health impact and cost of COVID-19 prophylaxis with monoclonal antibodies 86%
- COVID-SAFER: Deprescribing Guidance for Nirmatrelvir-ritonavir Drug Interactions in Older Adults 85%
Similar papers in this journal
- Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease using PET and Plasma Biomarkers 88%
- Altered brain energy metabolism related to astrocytes in Alzheimer’s disease 88%
- Development of Parkinson’s disease and its relationship with incidentally-discovered white matter disease and covert brain infarction in a real world cohort 87%
Similar papers in this journal
- Boston criteria v2.0 for cerebral amyloid angiopathy without hemorrhage: An MRI-neuropathological validation study 89%
- CSF p-tau181 Increases in Patients with Neuronal Intranuclear Inclusion Disease without Amyloid Burden 88%
- CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators 87%